Medical network - on January 12, roche rituxan injection (mabthera) global annual sales of about $7 billion, with annual sales of about $1.5 billion in China. Domestic although no targets with single drug resistance is approved, but existing 17 enterprises registered the product. In December 2016, the sea also received the CFDA cisco approval issued by the biological medicine "HSK - III - 001 injection of the drug approval documents of clinical trials, join rituxan market.
Rituxan public medical institutions in terminal sales of nearly 2 billion yuan
In 1997 the FDA approved the first monoclonal antibody (anti CD - 20 rituxan) successfully for the treatment of cancer patients. For nearly 20 years of monoclonal antibodies has experienced rapid development and the main drug for tumor therapy.
Rituxan injection for recurrence or resistance of follicular central type lymphoma (B cell non-hodgkin's lymphoma) treatment. According to senior m Intranet database (smart), from 2013 to 2015 in China's urban public hospitals, public hospitals at the county level, urban communities, towns and townships market to merge into the (hereinafter referred to as "public medical institution market) with annual sales of 1.482 billion yuan, 1.728 billion yuan and 1.951 billion yuan respectively.
0.5 g specifications highest bid price nearly twenty thousand yuan
The original drug prices generally high, rituxan injection in the winning of the six provinces in 2016, 0.5 g and 0.1 g specifications specifications of the highest bidding price in jiangxi province, 19875 yuan and 3937.5 yuan respectively, the lowest bid price in hebei province, 16041 yuan and 3416 yuan respectively. If you have the creature like medicine listed, its not easy influenced by drug policy prices, also suffered a competitive threat.
At home, rituxan injection price is higher, not easy to enter the national list of essential medicines and national health insurance directory, at the same time, rituxan injection has the rigid demand, if you have similar efficacy of drug market, the product will have a very good market prospect.
17 drug firms cluster focuses on "highland"
Rituxan injection in widely bullish situation, enterprises are entering the ranks of rituxan injection development, in addition to the sea, cisco has 16 companies aim at the product. Stroke of pharmaceutical citic countries health pharmaceutical co., LTD., Shanghai has completed phase iii, and batch production, hoped pharmaceutical is expected to be the first to eat crab "of the enterprise.
According to m Intranet MED drug approval database, according to China citic countries health and the drug approval documents have monoclonal antibody production. Citic country health have listed two single products, injection with type II tumor necrosis factor receptor of restructuring - antibody fusion protein (yi's) and restructuring CD25 humanized monoclonal antibody injection (health, pp). Sea is pharmaceutical single resistance products already on the market for injection with tumor necrosis factor receptor - human recombinant Ⅱ type antibody fusion protein (hk).
The above enterprises are in the research and development of monoclonal antibodies in a leading position in the field of enterprise, cinda creature by the department "one thousand plan" bio-pharmaceutical industry experts, such as national distinguished expert Dr YuDeChao founded in August 2011, shenzhou cells is the national "one thousand project" expert Dr Xie Liangzhi high-tech enterprise founded in 2002.
The enterprise strength strong, most enterprises have monoclonal antibody testing, but the cluster development and production of rituxan injection, after market saturation, bound to stay, will be eliminated some enterprises.
The rituxan market widely seen, strong market demand. First rituxan injection biological similar drug less susceptible to drug policy prices and competitive threats, to achieve the desired economic benefits. But many enterprises into rituxan injection of market competition, the profits were divided, later research and development enterprise is very difficult to have too much in return. |
